ETF Holdings Breakdown of RYTM

Stock NameRhythm Pharmaceuticals Inc
TickerRYTM(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS76243J1051
LEI529900JPNWXQ8DPLA551

News associated with RYTM

Stifel Financial Corp Has $1.09 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Stifel Financial Corp decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,516 shares of the company’s stock after selling 326 shares during the quarter. Stifel Financial Corp’s holdings in […] - 2025-05-09 08:27:01
First Trust Advisors LP Has $6.63 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
First Trust Advisors LP grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 67.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 118,337 shares of the company’s stock after buying an additional 47,575 shares during the period. First Trust Advisors LP owned 0.19% of […] - 2025-04-30 09:01:00
Legal & General Group Plc Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Legal & General Group Plc decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 7.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,803 shares of the company’s stock after selling 4,244 shares during the period. Legal & General […] - 2025-04-24 08:07:03
Invesco Ltd. Has $16.95 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Invesco Ltd. grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 14.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 302,846 shares of the company’s stock after purchasing an additional 38,429 shares during the period. Invesco Ltd.’s holdings in Rhythm Pharmaceuticals were worth $16,953,000 at the end of the […] - 2025-04-21 07:44:46
Trexquant Investment LP Takes $437,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Trexquant Investment LP bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 7,798 shares of the company’s stock, valued at approximately $437,000. A number of other large investors have also recently added to or reduced their stakes in RYTM. SRS Capital Advisors […] - 2025-04-13 08:31:02
Rhythm Pharmaceuticals (NASDAQ:RYTM) Raised to Buy at Bank of America
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm presently has a $63.00 price objective on the stock. Bank of America‘s price objective points to a […] - 2025-04-09 05:52:50
Norges Bank Acquires New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Norges Bank bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 205,649 shares of the company’s stock, valued at approximately $11,512,000. Norges Bank owned approximately 0.33% […] - 2025-04-08 07:48:51
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $91.00
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price target upped by Wells Fargo & Company from $80.00 to $91.00 in a research note published on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other research firms have also recently issued reports on RYTM. Morgan Stanley restated […] - 2025-04-08 05:52:50
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up After Analyst Upgrade
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price gapped up before the market opened on Monday after Wells Fargo & Company raised their price target on the stock from $80.00 to $91.00. The stock had previously closed at $46.95, but opened at $48.33. Wells Fargo & Company currently has an overweight rating on […] - 2025-04-08 05:12:52
Corebridge Financial Inc. Has $1.52 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Corebridge Financial Inc. decreased its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 7.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,220 shares of the company’s stock after selling 2,054 shares during the period. […] - 2025-04-03 08:49:02
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of “Moderate Buy” from Analysts
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year price […] - 2025-04-03 07:54:49
Cibc World Markets Corp Purchases New Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Cibc World Markets Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,123 shares of the company’s stock, valued at approximately $287,000. Several other institutional investors also recently modified their holdings of […] - 2025-03-26 08:08:48
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $66.00 at Needham & Company LLC
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66.00 in a research note released on Tuesday, Marketbeat reports. Needham & Company LLC currently has a buy rating on the stock. RYTM has been the topic of several other reports. The Goldman Sachs Group raised […] - 2025-03-19 06:47:04
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $68.27
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average […] - 2025-03-07 06:25:02
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $70.00 at HC Wainwright
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price objective hoisted by investment analysts at HC Wainwright from $69.00 to $70.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 31.53% from the company’s previous close. […] - 2025-03-05 07:04:55
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Handelsbanken Fonder AB
Handelsbanken Fonder AB lessened its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 11.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 17,021 shares of the company’s stock after selling 2,300 shares during the period. Handelsbanken Fonder AB’s holdings in Rhythm Pharmaceuticals were worth $953,000 at the end of […] - 2025-02-28 09:25:12
35,004 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 35,004 shares of the company’s stock, valued at approximately $1,960,000. Other institutional investors have also recently bought and sold shares of the company. Loomis […] - 2025-02-25 08:34:48
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year […] - 2025-02-14 08:22:55
abrdn plc Has $4.51 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
abrdn plc trimmed its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 28.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,517 shares of the company’s stock after selling 32,287 shares during the period. abrdn plc owned 0.13% […] - 2025-02-10 18:42:59
KBC Group NV Acquires 988 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
KBC Group NV increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 78.2% during the 4th quarter, Holdings Channel reports. The firm owned 2,251 shares of the company’s stock after acquiring an additional 988 shares during the quarter. KBC Group NV’s holdings in Rhythm Pharmaceuticals were worth $126,000 at the end of […] - 2025-02-08 08:36:51
Chicago Partners Investment Group LLC Reduces Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Chicago Partners Investment Group LLC cut its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 21.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,696 shares of the company’s stock after selling 1,029 shares during the quarter. Chicago Partners Investment […] - 2025-02-06 08:36:50
R Squared Ltd Acquires Shares of 780 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
R Squared Ltd acquired a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 780 shares of the company’s stock, valued at approximately $44,000. Other institutional investors and hedge funds have also recently modified their […] - 2025-02-03 08:46:52

RYTM institutional holdings

The following institutional investment holdings of RYTM have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 30,639USD 1,860,400
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 4,843USD 294,067
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 70,149USD 4,259,447
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 30,106USD 1,828,036
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 30,106USD 1,828,036 -6.4%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 92USD 5,586
Total =165,935 USD 10,075,572
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.